LifeWatch launches world's first medical smartphone

The smartphone has built-in sensors for monitoring heart rate, pulmonary function, blood sugar levels, body temperature and more.

Medical monitor developer LifeWatch AG (SWX:LIFE) has launched the world's first medical smartphone, for Android-powered devices. The smartphone has built-in sensors for monitoring heart rate, pulmonary function, blood sugar levels, body temperature and galvanic skin response (which measures psychological pressure), and other physiological variables. The system can also measure blood pressure with an attached sleeve, and can analyze blood samples.

LifeWatch has developed a range of wireless monitoring devices for emergency rooms and medical services, as well as for personal use, but this is the first time that it has combined these capabilities on a smartphone. Chinese branded mobile phone manufacturer TechFaith Wireless Communication Technology Ltd. (Nasdaq: CNTF) will manufacture the platform for LifeWatch.

LifeWatch develops the medical applications hardware and software that connects the hardware with the smartphone's systems. A German company is responsible for the design. LifeWatch invested several million dollars in the product.

The mobile-health interface is a hot development field in the world. There are various devices, not mobile phones, which collate and transmit medical data, and present them to users, and there are medical mobile apps for managing fitness, medication regimes, and even skin cancer diagnosis by photo analysis. There are also companies developing proprietary sensors for measuring a single medical variable, such as blood glucose levels or heartbeat, for integration with smartphones.

"Globes": Who is the medical smartphone intended for?

LifeWatch chairman and CEO Dr. Yacov Geva: "It is first of all intended for health-conscious consumers who have already recovered from, or are suffering from a chronic medical condition. At an advanced age, we're all suddenly liable to feel poorly in the middle of the day. With this phone, all the basic measurements are available to us. For patients, it enables effective management of their illness."

The device is not designed to diagnose heart attacks, but can monitor irregular heartbeat.

Is the device open to other medical devices and medical apps?

LifeWatch Technologies CEO Yair Tal: "That's the device's secret. Everything is inside, including medical apps, such as nutrition management, pedometer, and medication reminder. These already exist on the device and interface with data collected by us. Any app can be downloaded to the device, but there is no flow of data collected by the device to other apps. At the moment, there isn't an interface with other devices - there's no need for it."

To whom is the data produced by the smartphone sent?

Geva: "Where we operate emergency call centers, the data can be sent there. We currently have three call centers in the US, and we will establish a service in Israel to provide response to users of this product. That's part of our uniqueness as a company, which enables us to market this device. It is also possible to send the data to the patient's doctor and to an insurance company, but the data is primarily intended for the customers who are our target audience."

What regulations does this device require?

"The approval of health authorities is required as for any medical diagnostic device. We believe that we will obtain EU CE Mark certification by the end of this year and US Food and Drug Administration (FDA) approval the following year. It is already possible to market the device in Israel."

Aren't you worried about the rapid change in mobile phones?

"Progress in the mobile field is rapid, which is why we're readying to launch a device with new sensors and innovative capabilities in six to nine months. "

To get people to buy this device, you'll have to cause them to forego a device that is considered fun, such as the iPhone, for a device that marks them as sick. What target audience is so health conscious that it will do that?

"The product is a full telephone, which is intended for an audience that puts its health first. It is also possible to download apps onto it. We're in talks with mobile carriers in Israel and other countries to market the device through them.

LifeWatch's share price fell 2.2% in morning trading in Zurich today to CHF 7.51, giving a market cap of CHF 100 million.

Published by Globes [online], Israel business news - www.globes-online.com - on July 4, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
MORE FROM GLOBES
Erez Vigodman Teva boosted by European drug recommendations

Teva's share jumped 4% in Tel Aviv, after climbing 4.9% on Wall Street.

Partner/Orange Partner launches smartphone medical services

The new services includes prescriptions, hospital referrals, and confirmation of illness.

Reuven Krupik Clal Biotech unit PolyHeal nears licensing deal

PolyHeal has signed an MOU with a European drug company for an exclusive global license.

Nasdaq Galmed jumps on FDA hepatitis drug approval

The FDA awarded Fast Track Designation to aramchol for the treatment of Non-Alcoholic Steato-Hepatitis.

artificial sweeteners Weizmann Inst: Sweeteners cause diabetes, obesity

A study found that artificial sweeteners adversely affect intestinal bacteria.

BioCancell share jumps on positive cancer trial results

The clinical trials demonstrated safety and effectiveness of the treatment on high-risk bladder cancer patients.

Trendlines Group set for Toronto IPO

The technological incubators company is raising C$9 at a company value of C$80 million, after money.

Reuven Krupik Clal Biotech sues Hyperion for $200m

Clal Biotechnology alleges Hyperion made "rash and ill-considered" decisions in the Andromeda affair.

pharmaceuticals Clal Biotech: No evidence of misconduct by us

Clal Biotech says documents it was shown by Hyperion do not indicate it committed any misconduct regarding Andromeda.

Soroka Hospital  picture: Eyal Yitzhar Visiting Israel’s wounded at Soroka

Soroka Medical Center in Beersheva, the Israeli hospital closest to Gaza, bears the medical brunt of Operation Protective Edge.

Twitter Facebook Linkedin RSS Newsletters גלובס